|Cash flow from operations||$1.5 billion|
|GAAP EPS||$0.35||984 million shares|
|Non-GAAP EPS||$1.31||1,044 million shares|
Israel's largest firm is also searching for a chief financial officer in which three candidates are vying for the position.
The approval marks the first time that an immunotherapy has been combined with another drug to kill cancer cells more effectively.